HOHL BENJAMIN (CHIEF FINANCIAL OFFICER) sold 10.6% of their position (6.02K shares) of ENLIVEN THERAPEUTICS, INC. on the open market
Open‑market sale worth $263.6K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 3 sales
Filed: 6/22/2026ACC: 0001882764-26-000005
Officer· CHIEF FINANCIAL OFFICER
Since Feb 2026
-6.02K
Net shares
Net seller
$263.6K
Total sold
3
Open market trades
0B · 3S
5
Total transactions
6.02K acquired · 12.04K disposed
Non-Derivative Transactions4
Common Stock
Direct
Shares
+6.02K
Price / share
$2.48
Trade value
$14.92K
% of position
11.8%
6/17/2026
51K→57.02K
Common Stock
Direct
Shares
−1.38K
Price / share
$42.78
Trade value
$59K
% of position
2.4%
6/17/2026
57.02K→55.64K
Common Stock
Direct
Shares
−3.40K
Price / share
$43.86
Trade value
$149.18K
% of position
6.1%
6/17/2026
55.64K→52.24K
Common Stock
Direct
Shares
−1.24K
Price / share
$44.75
Trade value
$55.40K
% of position
2.4%
6/17/2026
52.24K→51K
Total
Net shares
+0.00
Net value
-$248.65K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 6/17/2026 | M · Option Exercise | +6.02K | $2.48 | $14.92K | 11.8% | 51K | 57.02K |
| Common Stock Direct | 6/17/2026 | S · Sale | −1.38K | $42.78 | $59K | 2.4% | 57.02K | 55.64K |
| Common Stock Direct | 6/17/2026 | S · Sale | −3.40K | $43.86 | $149.18K | 6.1% | 55.64K | 52.24K |
| Common Stock Direct | 6/17/2026 | S · Sale | −1.24K | $44.75 | $55.40K | 2.4% | 52.24K | 51K |
| Total | +0.00 | -$248.65K | ||||||
Derivative Transactions1
Stock Option (right to buy)
Direct
Converts to
Common Stock
6.02K shares
Shares
−6.02K
Strike price
2.48
Held after
86.04K
Exercisable
—
6/17/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) Direct | Common Stock6.02K shares | 6/17/2026 | M · Option Exercise | −6.02K | 2.48 | — | 86.04K |